4D Molecular Therapeutics, Inc. Common Stock FDMT

4D Molecular Therapeutics, Inc. es una empresa de biotecnología en etapa avanzada que avanza en terapéuticas duraderas y dirigidas a enfermedades. El candidato principal de la compañía, 4D-150, está diseñado para ser una terapia base que forme la base del tratamiento de enfermedades vasculares retinianas cegadoras al proporcionar una entrega sostenida de varios años de anti-VEGF (aflibercept y anti-VEGF-C) con una sola inyección intravítrea segura, lo que reduce sustancialmente la carga de tratamiento asociada con las inyecciones actuales. Su principal indicación para 4D-150 es la degeneración macular relacionada con la edad húmeda, que se encuentra en desarrollo de Fase III, y la segunda indicación es el edema macular diabético. La compañía está desarrollando 4D-710 para el tratamiento de una variedad de personas con fibrosis quística independientemente de su mutación específica de CFTR. 4D-710 es un candidato a medicina genética en investigación que utiliza el vector A101 para el tratamiento de la enfermedad pulmonar de fibrosis quística. Los programas no principales de la compañía incluyen 4D-175, 4D-725 y 4D-310.

• GlobeNewswire Inc. 25 ago

  4DMT to Participate in Upcoming Investor Conferences

  4DMT announced management presentations at three major healthcare investor conferences in September 2026. The company reported completion of enrollment for its lead product 4D-150 Phase 3 trial (4FRONT-2) for wet AMD with topline data expected in H2 2027, and positive 2-year data from the 4D-150 PRISM trial. 4D-710, the company's genetic medicine for cystic fibrosis, continues development.

  

• GlobeNewswire Inc. 18 jul

  4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

  4D Molecular Therapeutics (4DMT) announced positive 2-year results from its PRISM Phase 2b clinical trial of 4D-150, an intravitreal gene therapy for wet age-related macular degeneration (AMD). The single-dose treatment demonstrated consistent maintenance of visual acuity and anatomic control with 78-87% reduction in treatment burden compared to standard aflibercept injections. The therapy was well-tolerated with no new safety concerns or intraocular inflammation cases beyond the first 6 months.

  

• GlobeNewswire Inc. 29 jun

  4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

  4D Molecular Therapeutics (FDMT) announced a strategic credit facility agreement with Hercules Capital (HTGC) for up to $200 million in non-dilutive financing. The company drew an initial $20 million at closing, with additional tranches available through 2027 and upon achievement of certain milestones. This financing strengthens 4DMT's cash position of $458 million as of March 31, 2026, and provides operational flexibility as the company advances its lead product 4D-150 through Phase 3 development for wet AMD and DME.

  

• GlobeNewswire Inc. 18 jun

  Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape

  DelveInsight's 2026 report reveals a robust AMD clinical trial pipeline with 90+ active players developing 100+ pipeline drugs across various clinical stages. The report highlights promising therapies including elamipretide, 4D-150, MK-8748, and SAR402663, with approximately 15+ drugs in late-stage development. Recent advances include Merck's Phase IIb/III trial initiation for MK-8748, 4D Molecular Therapeutics' Phase III enrollment completion for 4D-150, and FDA fast-track designation for SAR402663.